- HOME
- Introduction
- Research
- NKO-035 PET clinical research
2) Diagnostic PET/SPECT【Oncology PET】
NKO-035 PET clinical research
New PET probe (F-18 NKO-035 injection), which has high selectivity for amino acid transporter (LAT1) highly expressed in cancer cells, has developed in collaboration with department of Bio-systems Pharmacology (Prof. Yoshikatsu Kanai), and stable mass production was enabled by new labelling method.
In November 2019, the world's first in human clinical trial was conducted using F-18 NKO-035 solution in healthy adults to confirm its safety in humans.
In the future, by conducting clinical trials to confirm the efficacy in cancer patients, we can reduce false-positive findings for inflammatory lesions, which were difficult to accurately being diagnosed with conventional FDG-PET. It is expected to lead to highly accurate cancer diagnosis.
Due to remarkable LAT1-selective accumulation, no significant accumulation except for excretion of probes into urine is observed
| NKO-035 | FDG | |
|---|---|---|
| Radiolabeled amino acid analog | Radiolabeled glucose analog | |
| Tracer uptake in tumor tissues | High | High |
| Tracer uptake in inflamed lesions | None | Moderate ~ high |
Comparison between new PET probe and conventional PET probe